SeaStar Medical (NASDAQ:ICU) Issues Earnings Results

SeaStar Medical (NASDAQ:ICU) announced its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02, Zacks reports. The business had revenue of $0.18 million for the quarter, compared to the consensus estimate of $0.25 million. SeaStar Medical had a negative net margin of 1,551.08% and a negative return on equity of 2,379.28%.

SeaStar Medical Stock Down 17.4%

NASDAQ:ICU traded down $0.08 during trading hours on Friday, reaching $0.38. The company had a trading volume of 1,908,280 shares, compared to its average volume of 795,491. The firm has a market capitalization of $12.96 million, a PE ratio of -0.23 and a beta of -1.06. The stock has a 50-day moving average of $0.67 and a two-hundred day moving average of $0.82. SeaStar Medical has a one year low of $0.31 and a one year high of $3.07.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of SeaStar Medical in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, SeaStar Medical currently has a consensus rating of “Sell”.

Institutional Trading of SeaStar Medical

An institutional investor recently raised its position in SeaStar Medical stock. XTX Topco Ltd raised its position in shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) by 395.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 60,983 shares of the company’s stock after buying an additional 48,674 shares during the period. XTX Topco Ltd owned about 0.54% of SeaStar Medical worth $26,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.69% of the company’s stock.

SeaStar Medical Company Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome.